Categories: News

GVB Biopharma Begins Sales of CBGa Isolate

LAS VEGAS, March 30, 2022 /PRNewswire/ — GVB Biopharma, a biopharmaceutical company specializing in hemp and cannabis-related white-label consumer products, announced today that its website has launched sales of cannabigerolic acid isolates, popularly known as CBGa. 

CBGa is the carboxylic acid form of cannabigerol, known as CBG. It is a precursor molecule to delta-9-tetrahydrocannabinol, one of the primary psychoactive cannabinoids in Cannabis sativa. CBGa is non-intoxicating, and has unique benefits described by scientific literature and by consumers. CBGa is important for cannabinoid research and production.

Recently, CBGa has been the focus of high-profile research studies on COVID-19 transmission and on epilepsy management. In January, a study conducted by Oregon State University was published in the peer-reviewed Journal of Natural Products. The research indicated CBGa has the potential to prevent cellular transmission of the SARS-CoV-2 coronavirus that causes COVID-19. A study published in the British Journal of Pharmacology last August demonstrated that CBGa had potent anti-seizure effects in certain mouse models of epilepsy.

GVB Biopharma’s CBGa isolate product contains 95–99% CBGa.

As the standard bearer for high-integrity manufacturing and processing in the hemp cannabinoid industry, GVB Biopharma is proud to introduce one of its newest products in CBGa. GVB’s unparalleled commitment to generating the highest quality consumer products begins with its state-of-the-art hemp processing facilities in central Oregon. It is further supported by white-label consumer product manufacturing operations in Las Vegas, administrative headquarters in Los Angeles and an expanding palette of national sales offices. GVB’s vast national and global reach allows it to meet the exploding demand for hemp cannabinoids and be an indispensable industry partner for entrepreneurs and brands serving this market’s needs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/gvb-biopharma-begins-sales-of-cbga-isolate-301513931.html

SOURCE GVB Biopharma

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

19 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

19 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago